Donald Brunet

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

A full genome search in multiple sclerosis

George C. Ebers, Kim Kukay, Dennis E. Bulman et al. · Nature Genetics · 1996 · 662 citations

Medicine, Genetics, Complex Disease +5

A Population-Based Study of Multiple Sclerosis in Twins

George C. Ebers, Dennis E. Bulman, A. Dessa Sadovnick et al. · New England Journal of Medicine · 1986 · 638 citations

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Electrical Dose and Seizure Threshold: Relations to Clinical Outcome and Cognitive Effects in Bifrontal, Bitemporal, and Right Unilateral ECT

Nicholas J. Delva, Donald Brunet, Emily R. Hawken et al. · Journal of Ect · 2000 · 67 citations

Neuropsychology, Bifrontal Electroconvulsive Therapy, Electroconvulsive Therapy +22